CATAPRES Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Catapres, and when can generic versions of Catapres launch?

Catapres is a drug marketed by Boehringer Ingelheim and Lavipharm and is included in two NDAs.

The generic ingredient in CATAPRES is clonidine. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the clonidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Catapres

A generic version of CATAPRES was approved as clonidine by DIFGEN PHARMS on August 18^th, 2009.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for CATAPRES?
What are the global sales for CATAPRES?
What is Average Wholesale Price for CATAPRES?

Summary for CATAPRES

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	205
Clinical Trials:	19
Patent Applications:	4,355
Drug Prices:	Drug price information for CATAPRES
Drug Sales Revenues:	Drug sales revenues for CATAPRES
What excipients (inactive ingredients) are in CATAPRES?	CATAPRES excipients list
DailyMed Link:	CATAPRES at DailyMed

Drug patent expirations by year for CATAPRES

Recent Clinical Trials for CATAPRES

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rigshospitalet, Denmark	Phase 2/Phase 3
Deventer Ziekenhuis	Phase 3
NHS Lothian	Phase 3

See all CATAPRES clinical trials

US Patents and Regulatory Information for CATAPRES

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Lavipharm	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for CATAPRES

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-003	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Boehringer Ingelheim	CATAPRES	clonidine hydrochloride	TABLET;ORAL	017407-002	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for CATAPRES

See the table below for patents covering CATAPRES around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
United Kingdom	1034938		⤷ Sign Up
Denmark	108364		⤷ Sign Up
Denmark	117000		⤷ Sign Up
Cyprus	416	2-Aryl-amino-1,3-diazacyclopentenes	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for CATAPRES

Recent Clinical Trials for CATAPRES

Make Better Decisions: Try a trial or see plans & pricing